免疫检查点抑制剂治疗相关的假性进展和超进展

Pseudoprogression and hyperprogression related to immune checkpoint inhibitors treatment

目前,免疫检查点抑制剂在临床上应用广泛,假性进展和超进展作为免疫检查点抑制剂治疗肿瘤过程中出现的独特现象,近年来被广泛关注。如何正确评估免疫检查点抑制剂如抗CTLA-4单抗(伊匹木单抗)和抗PD-1单抗(纳武利尤单抗和帕博利珠单抗)的疗效已成为挑战。本文综述了免疫检查点抑制剂治疗后发生假性进展和超进展的研究现状,以期为肿瘤的临床治疗、假性进展和超进展的识别等提供参考。

At present,immune checkpoint inhibitors are widely used in clinical.As one of the unique phenomena in the treatment of tumor,pseudoprogression and hyperprogression have been widely focused in recent years.How to properly evaluate the efficacy of immune checkpoint inhibitors such as anti-CTLA-4 monoclonal antibodies(ipilimumab)and antiPD-1 monoclonal antibodies(nivolumab and pembrolizumab)is a challenge.The research status of pseudoprogression and hyperprogression after immune checkpoint inhibitors treatment,so as to provide references for the clinical treatment of tumor and the recognition of pseudoprogression and hyperprogression were reviewed in this article.